Adicet Bio (NASDAQ: ACET)
$0.81
(-2.0%)
-$0.02
Price as of September 30, 2025, 3:56 p.m. ET
Adicet Bio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Adicet Bio Company Info
Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.
News & Analysis
Featured Article
Adicet Bio (ACET) Q2 Loss Widens 3%
Motley Fool Markets Team | Aug 7, 2025
Featured Article
3 Biotech Stocks That Could Make You Richer in February (and Beyond)
These companies' share prices could rise in the short term, but their long-term opportunities are even better.
Keith Speights, David Jagielski, and Prosper Junior Bakiny | Feb 5, 2022
3 Biotech Stocks That Could Double in 2022
Keith Speights, David Jagielski, and Prosper Junior Bakiny | Jan 3, 2022
They're risky. But with the high risk comes the potential for high rewards.
Why Adicet Bio Stock Is Skyrocketing Today
Keith Speights | Dec 6, 2021
The company reported positive interim results from a phase 1 study.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.